One analyst who aimed at bringing only the negatives about biotech has finally succeeded in convincing other critics and media bloggers that Gilead would not be good for investment until the firm acquires a company that can expand its meager oncology franchise. His story became the melody hummed by every blogger, ignoring the fact that the firm’s revenues and income have doubled overnight after its all oral HCV treatments’ were approved and marketed.
The success of Gilead’s HCV treatments, in addition to the HIV improved and facilitated treatments did not only fill the firm . . .